Laura Hansen

Laura leads Investor Relations at Denali, offering more than two decades of experience in corporate and scientific communications for biotech companies.

Prior to Denali, she was Vice President of Corporate Affairs at BlackThorn Therapeutics, a privately held company focused on developing precision medicines for neuropsychiatric disorders. Before joining BlackThorn, she was Vice President of Investor Relations at Aimmune Therapeutics, Inc., a leading food allergy therapeutics company. Prior to that, she held positions in corporate communications at Threshold Pharmaceuticals, Inc., and FibroGen, Inc. At both companies, she was also responsible for scientific communications related to novel therapeutic platforms in oncology, fibrosis, and anemia.

Laura has a Ph.D. in Biological Sciences and a B.S. in Zoology from The University of Texas at Austin.